


Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 15.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Merck Serono
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 5




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Levothyroxine
EMR 200125-001


Bioequivalence EMR200125-001 Page 906 of 1628 ulation vs. old formulation

Merck Serono
EMR 200125-001

Page 149 of 216
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1 3




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: [REDACTED]




③: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)


Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




③: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 3




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)


Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)


Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1000000000



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: : 2




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1001



Ⓔ: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)


Subject ID/Random Number: }



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Merck Serono
EMR 200125-001
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas*

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas




Merck Serono
EMR 200125-001

Page 184 of 216

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 00000000




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



⓪: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)


Subject ID/Random Number: [REDACTED]



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas


Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

```
/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/Figure
15.4.2.9.sas
```



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210999_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.aas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: _____




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population).

Subject ID/Random Number: 100000000




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: [REDACTED]



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: .




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




```
/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/Figure
15.4.2.9.sas
```



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Merck Serono
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: --




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)


Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

Merck Serono
EMR 200125-001

Page 210 of 216
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Merck Serono
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.C.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

Merck Serono
EMR 200125-001

Page 216 of 216
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure
15.4.2.9.sas

